Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$513000.0.

  • Northwest Biotherapeutics' Cash from Investing Activities fell 19147.73% to -$513000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$988000.0, marking a year-over-year increase of 2703.1%. This contributed to the annual value of -$1.0 million for FY2024, which is 7049.75% up from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Cash from Investing Activities of -$513000.0 as of Q3 2025, which was down 19147.73% from -$304000.0 recorded in Q2 2025.
  • Northwest Biotherapeutics' Cash from Investing Activities' 5-year high stood at -$58000.0 during Q1 2022, with a 5-year trough of -$2.7 million in Q3 2021.
  • Over the past 5 years, Northwest Biotherapeutics' median Cash from Investing Activities value was -$418000.0 (recorded in 2023), while the average stood at -$751473.7.
  • In the last 5 years, Northwest Biotherapeutics' Cash from Investing Activities soared by 8974.36% in 2022 and then plummeted by 219827.59% in 2023.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Cash from Investing Activities stood at -$1.6 million in 2021, then plummeted by 39.09% to -$2.2 million in 2022, then skyrocketed by 80.65% to -$418000.0 in 2023, then surged by 81.34% to -$78000.0 in 2024, then tumbled by 557.69% to -$513000.0 in 2025.
  • Its Cash from Investing Activities was -$513000.0 in Q3 2025, compared to -$304000.0 in Q2 2025 and -$93000.0 in Q1 2025.